Streetbeat News

Equity Actions

VYGR

Voyager Therapeutics has announced a proposed public offering aiming to raise $100 million. The proceeds from the offering are expected to be used to fund the company's clinical trials, research and development, and for general corporate purposes. This move could potentially dilute current shareholders but also provides the company with additional capital to advance its projects.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 9:15 pm

KYMR

Kymera Therapeutics has announced a public offering of $250 million of its common stock and pre-funded warrants. The offering is solely by Kymera, with an additional option for underwriters to purchase up to $37.5 million more of its common stock at the public offering price, minus discounts and commissions.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 9:02 pm

SPWR

Analyst ratings for SunPower (NASDAQ:SPWR) show a mix of opinions, with recent evaluations leading to a decrease in the average 12-month price target from $7.43 to $4.88, a 34.32% drop. Analysts from firms like Mizuho, Goldman Sachs, and Barclays have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. SunPower's financials indicate challenges with a revenue decline of -9.59%, a net margin of -8.68%, and a high debt-to-equity ratio of 0.86, suggesting potential financial strain.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 9:01 pm

ADC

Agree Realty (NYSE:ADC) has received mixed analyst ratings over the past quarter, with 1 bullish, 2 somewhat bullish, and 2 indifferent. The average 12-month price target is now $63.4, down from $70.25, with a high estimate of $67 and a low of $61. Analysts from RBC Capital, Exane BNP Paribas, Mizuho, and Truist Securities have adjusted their price targets and ratings, reflecting changes in market dynamics and company performance. Agree Realty, a real estate investment trust, has shown a positive revenue trend with a 24.3% growth rate and a net margin of 28.92%, but its ROE of 0.8% is below industry averages. Its ROA of 0.53% and a debt-to-equity ratio of 0.44 indicate strong financial health and sound financial structure.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 9:00 pm

PCH

PotlatchDeltic (NASDAQ:PCH) was analyzed by 4 analysts, with all maintaining an 'Indifferent' rating. The average 12-month price target is now $49.25, down from $52.33, indicating a 5.89% decrease. Analysts from Truist Securities and RBC Capital adjusted their price targets, with Truist raising their target to $51.00 from $50.00 and then lowering it to $50.00 from $55.00, while RBC Capital lowered their target to $48.00 from $52.00. PotlatchDeltic is a REIT with segments in timberlands, wood products, and real estate, facing revenue challenges and below-average profitability metrics.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 9:00 pm

JHG

Analysts have provided mixed reviews on Janus Henderson Group (NYSE:JHG) with 3 indifferent and 1 somewhat bearish rating. The 12-month price target average has decreased to $26.07 from $26.90. Analysts from TD Cowen, Deutsche Bank, JP Morgan, and Citigroup have adjusted their price targets and ratings, reflecting market conditions and company performance. Janus Henderson Group, an investment management service provider, has shown a revenue growth of 1.58% as of September 30, 2023, but lags behind industry peers and exhibits lower profitability and efficiency metrics.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 9:00 pm

TMO

Thermo Fisher Scientific (NYSE:TMO) has seen unusual options activity, with a mix of bullish and bearish trades. Analysis of 11 trades shows a slight majority of bullish sentiment, with 54% of traders betting on the upside. The options trades suggest a target price range of $220 to $670 over the next three months. Notable trades include bullish calls for January 2024 and 2025 expirations, and bearish puts for February 2024. Thermo Fisher operates in four segments, with lab products and services being the largest. The stock is slightly up with a potential overbought RSI, and earnings are expected in 27 days.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 8:49 pm

KROS

Keros Therapeutics has announced the pricing of an upsized public offering, planning to raise $140 million through the sale of 3.5 million shares at $40 each. This has led to an increase in the trading price of Keros Therapeutics shares.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 8:37 pm

EPD

Enterprise Prods Partners Inc. (NYSE:EPD) stock is currently trading at $27.15, marking a 0.56% increase. Over the past month, EPD's stock has risen by 1.98%, and over the past year, by 7.08%. The company's P/E ratio of 10.98 is lower than the industry average of 24.97, which could indicate that the stock is undervalued or that shareholders have lower growth expectations. Investors are advised to consider the P/E ratio alongside other financial metrics and qualitative analysis for a comprehensive investment decision.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 8:01 pm

PFG

Analysts have provided mixed reviews on Principal Financial Group (NASDAQ:PFG) over the past three months, with a consensus of 4 indifferent, 2 somewhat bearish, and 1 bearish rating. The average 12-month price target is $72.71, with a high of $83.00 and a low of $62.00, marking a 2.31% decrease in the average target. Recent actions include both raised and lowered price targets and ratings by analysts from Evercore ISI Group, Morgan Stanley, Piper Sandler, Citigroup, Wells Fargo, and Barclays. Principal Financial Group operates in investment management and insurance, with a strong market cap, net margin, ROE, and ROA, but a negative revenue trend over the last quarter.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 8:01 pm